QCG
MREO

Quadrant Capital Group’s Mereo BioPharma MREO Stock Holding History

Quadrant Capital Group’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-398
Closed -$1.43K – 2779
2024
Q2 		$1.43K Sell
398
-341
-46% -$1.1K ﹤0.01% 2523
2024
Q1 		$2.44K Buy
+739
New +$2.5K ﹤0.01% 2470
2021
Q3 		– Sell
-3,657
Closed -$12K – 2593
2021
Q2 		$12K Buy
+3,657
New +$12.3K ﹤0.01% 1487

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Quadrant Capital Group's MREO Position: Q3 2024 in Review

Quadrant Capital Group sold out of Mereo BioPharma (MREO) in Q3 2024, closing a stake of 398 shares — an estimated $1.43K sold.

Quadrant Capital Group first reported a position in MREO in Q2 2021 and held it in 3 quarters. The position peaked at $12K in Q2 2021. 77 funds tracked by Wall St. Rank hold MREO as of Q3 2024.

  • Quadrant Capital Group reported no remaining Mereo BioPharma position as of Q3 2024 after selling out during the quarter.
  • Quadrant Capital Group sold 398 Mereo BioPharma shares in Q3 2024, an estimated $1.43K.
  • Quadrant Capital Group first reported a position in Mereo BioPharma in Q2 2021 and held it in 3 quarters.
  • Quadrant Capital Group's Mereo BioPharma position peaked at $12K in Q2 2021.
  • 77 funds tracked by Wall St. Rank held Mereo BioPharma as of Q3 2024.

Based on Quadrant Capital Group's 13F filing for Q3 2024, filed 12 Nov 2024.